Bank of America Corp DE increased its stake in shares of MacroGenics, Inc. (NASDAQ: MGNX) by 30.7% d

Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this

The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and rai

MacroGenics (MGNX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Esti

Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.27) per share which missed the analyst co

ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in

ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage

Shares of MacroGenics, Inc. (NASDAQ: MGNX - Get Free Report) have been given an average rating of "H

MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pip

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in

Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specifie

Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find

ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in

ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage

ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutica

MacroGenics (MGNX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Esti

Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.58) per share which beat the analyst cons

ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage

Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising gui

•MacroGenics to receive $122. 5 million upfront payment from Bora upon closing•Transaction includes

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely ear

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in

• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the p

Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises th

• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers• On track to pr

• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers   • On track to

Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises th

MacroGenics sees stock decline after FDA places partial clinical hold on Phase 2 LINNET study due to

Macrogenics (NASDAQ:MGNX) reported quarterly earnings of $0.27 per share which beat the analyst cons

HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering,

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Neutral and

Stifel analyst Stephen Willey maintains Macrogenics (NASDAQ:MGNX) with a Hold and lowers the pric

Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers th

Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.65) per share which beat the analyst cons

HC Wainwright & Co. analyst Robert Burns maintains Macrogenics (NASDAQ:MGNX) with a Neutral a